When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BBIO - An Update On Ascendis Pharma's Path To Profitability
BridgeBio Pharma Inc.
2024-05-08 06:55:36 ET
Summary
Ascendis Pharma is expected to achieve cash flow break even by the end of 2024, driven by its core franchise of medicines for rare endocrinology conditions.
The company's approved drug, Skytrofa, has shown strong sales and has the potential to be a blockbuster.
Ascendis Pharma's TransCon PTH, a parathyroid hormone replacement therapy, is awaiting FDA approval and has the potential to capture a significant market share in the treatment of hypoparathyroidism.